- Home
- NVRI vs DAWN Comparison
NVRI vs DAWN Comparison
Compare NVRI & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVRI
- DAWN
- Stock Information
- Founded
- NVRI 1853
- DAWN 2018
- Country
- NVRI United States
- DAWN United States
- Employees
- NVRI N/A
- DAWN N/A
- Industry
- NVRI Diversified Commercial Services
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- NVRI Miscellaneous
- DAWN Health Care
- Exchange
- NVRI Nasdaq
- DAWN Nasdaq
- Market Cap
- NVRI 756.7M
- DAWN 624.8M
- IPO Year
- NVRI N/A
- DAWN 2021
- Fundamental
- Price
- NVRI $9.78
- DAWN $6.75
- Analyst Decision
- NVRI Hold
- DAWN Strong Buy
- Analyst Count
- NVRI 1
- DAWN 7
- Target Price
- NVRI $10.00
- DAWN $27.86
- AVG Volume (30 Days)
- NVRI 806.7K
- DAWN 2.1M
- Earning Date
- NVRI 08-05-2025
- DAWN 08-05-2025
- Dividend Yield
- NVRI N/A
- DAWN N/A
- EPS Growth
- NVRI N/A
- DAWN N/A
- EPS
- NVRI N/A
- DAWN N/A
- Revenue
- NVRI $2,242,873,000.00
- DAWN $187,638,000.00
- Revenue This Year
- NVRI $0.02
- DAWN $16.42
- Revenue Next Year
- NVRI $3.71
- DAWN $47.52
- P/E Ratio
- NVRI N/A
- DAWN N/A
- Revenue Growth
- NVRI N/A
- DAWN 2190.50
- 52 Week Low
- NVRI $4.72
- DAWN $5.64
- 52 Week High
- NVRI $11.95
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- NVRI 61.61
- DAWN 54.42
- Support Level
- NVRI $7.70
- DAWN $6.08
- Resistance Level
- NVRI $9.04
- DAWN $6.42
- Average True Range (ATR)
- NVRI 0.50
- DAWN 0.32
- MACD
- NVRI 0.09
- DAWN -0.01
- Stochastic Oscillator
- NVRI 83.67
- DAWN 72.40
About NVRI Enviri Corporation
Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.